IOL Chemicals Reports 9.8% Revenue Growth and 19.5% EBITDA Jump in Q1 Aug 13, 2025
IOL Chemicals Unveils Strategic Expansion Plan Amid Strong Q1 Performance Aug 07, 2025
IOL Chemicals and Pharmaceuticals Reports Strong Q1 Performance, Plans UK Subsidiary and Minoxidil Production Aug 07, 2025
IOL Chemicals Secures EU REACH Registration for Acetic Anhydride Jun 13, 2025
More news about IOL Chemicals & Pharmaceuticals
16May 25
IOL Chemicals: Q4 Net Profit Rises 13.7%, Margins Expand
IOL Chemicals and Pharmaceuticals Ltd announced impressive Q4 financial results. EBITDA increased by 28.5% to ₹62.60 crore, with EBITDA margin improving to 11.80%. Net profit rose by 13.7% to ₹31.42 crore, while revenue grew by 4.7% to ₹527.70 crore. The company demonstrated improved operational efficiency and effective cost management.
24Mar 25
IOL Chemicals and Pharma Boosts Production Capacity with New Paracetamol Unit and Clopidogrel Expansion
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has significantly expanded its production capabilities. The company launched a new Paracetamol production unit with a capacity of 10,800 MTPA, increasing total capacity to 14,400 MTPA. IOLCP also expanded its Clopidogrel Bisulphate manufacturing capacity from 180 MTPA to 240 MTPA. The Paracetamol expansion cost Rs 155.51 crore, while the Clopidogrel expansion required Rs 7.87 crore, both funded through internal accruals. The new Paracetamol unit includes backward integration with in-house production of key intermediates.